Stay up-to-date on the latest stock market upgrades and downgrades on Wall Street, including companies like Roku, Palo Alto ...

Alzheimer's wonder drugs aren't yet delivering on their promise. American researchers have come up with a brand new idea, a ...

Eli Lilly & Co’s Alzheimer’s drug won’t be made available for patients using England’s National Health Service, after the drug cost regulator deemed its benefits were too small to justify the price.

As of H1 2024, 62% of the firm’s revenue came from its portfolio of drugs targeting multiple sclerosis. Within this portfolio ...

"Samsung Biologics inks $668m manufacturing deal with European pharma " was originally created and published by ...

Happenings in Boston’s life sciences ecosystem this past week include the departure of a general partner from Apple Tree Partners for another firm, Kronos Bio seeks "strategic alternatives" and new ...

On Tuesday, UCB SA (OTC:UCBJY) (OTC:UCBJF) and Biogen Inc. (NASDAQ:BIIB) presented detailed results from the Phase 3 PHOENYCS ...

Today, Benzinga 's options scanner spotted 9 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 22% bullish and 66%, bearish. Out ...

Negative results from a Huntington’s trial add to a calamitous year for Sage, which last month decided to overhaul its ...

In a first-of-its-kind trial, physicians will review neurofilament test results with patients and decide whether to continue ...

Sage Therapeutics will stop development of its experimental drug to treat cognitive impairment in patients with Huntington's disease after it failed a mid-stage study, the drug developer said on ...

Roche's spinal muscular atrophy (SMA) medicine Evrysdi only gained its FDA approval in 2020, but generics companies are ...